ArticleThe pharmacogenomics journal2017
Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?
Abstract read
In one paragraph
Article in The pharmacogenomics journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.Clinical pharmacology and therapeutics · 2019Pooled it
- Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation.Clinical and translational science · 2026Article
- Cancer patients' perspectives and practices regarding pharmacogenomic testing and its cost.Frontiers in pharmacology · 2026Article
- Analyzing pharmacogenetics cost effectiveness and savings across common health conditions in the United States.The pharmacogenomics journal · 2025Review
- A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study).The pharmacogenomics journal · 2025Article
- Patients' Experiences of a Precision Medicine Clinic.Journal of patient experience · 2024Article
- Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States.Frontiers in pharmacology · 2023Article
- Public perceptions of pharmacogenomic services in Ireland - Are people with chronic disease more likely to want service availability than those without? A questionnaire study.Exploratory research in clinical and social pharmacy · 2022Article
- A Theory-Informed Systematic Review of Barriers and Enablers to Implementing Multi-Drug Pharmacogenomic Testing.Journal of personalized medicine · 2022Review
- Public Attitudes toward Pharmacogenomic Testing and Establishing a Statewide Pharmacogenomics Database in the State of Minnesota.Journal of personalized medicine · 2022Article
- Article
- Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved.Frontiers in genetics · 2022Article
- Pharmacogenomic-based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system.Clinical and translational science · 2021Article
- Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis.Translational psychiatry · 2021Review
- Moving Pharmacogenetics Into Practice: It's All About the Evidence!Clinical pharmacology and therapeutics · 2021Review
- Patients with geographic barriers to health care access are prescribed a higher proportion of drugs with pharmacogenetic testing guidelines.Clinical and translational science · 2021Article
- Implementation of a Pharmacogenomic Testing Service through Community Pharmacy in the Netherlands: Results from an Early Service Evaluation.Pharmacy (Basel, Switzerland) · 2021Article
- The economics of precision health: preventing air pollution-induced exacerbation in asthma.ERJ open research · 2021Article
- Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization.Pharmaceutics · 2020Review
- DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.Pharmacotherapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
S J BielinskiDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
J L St SauverDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
J E OlsonDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
M L WielandDivision of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
C R VitekCenter for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
E J BellDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
M E Mc GreeRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
D J JacobsonRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
J B McCormickBiomedical Ethics Program, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
P Y TakahashiDivision of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
J L BlackDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
P J CaraballoDivision of General Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
R R SharpBiomedical Ethics Program, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
T J BeebeRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
R M WeinshilboumDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
L WangDivision of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
V L RogerDivision of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Funding
Genomic Basis of Susceptibility to COVID-19 Infection and its ComplicationsU01HG006379 · NHGRI · MAYO CLINIC ROCHESTER · PI Richard R. Sharp · 2011 to 2026
$16.5MPharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8MRochester Epidemiology ProjectR01AG034676 · NIA · MAYO CLINIC ROCHESTER · PI ROCCA, WALTER A, ST SAUVER, JENNIFER LYNN · 2010 to 2019
$9.5MCARDIOVASOLOGYT32HL007111 · NHLBI · MAYO CLINIC ROCHESTER · PI Barry A. Borlaug · 1985 to 2026
$8.7MINHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9MPharmacogenomics of Breast Cancer Adjuvant ChemotherapyU01HG005137 · NHGRI · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2009 to 2011
$2.1MPharmacogenomics and Mechanisms of Cytidine AnaloguesR01CA138461 · NCI · MAYO CLINIC ROCHESTER · PI WANG, LIEWEI · 2009 to 2013
$1.5MNCI NIH HHS R01 CA138461NHGRI NIH HHS U01 HG005137NHGRI NIH HHS U01 HG006379NHLBI NIH HHS T32 HL007111NIA NIH HHS R01 AG034676NIGMS NIH HHS R01 GM028157NIGMS NIH HHS U19 GM061388
Abstract
PubMed holds no abstract for this paper.
Indexed as
Financing, PersonalHealth Care CostsHealth ExpendituresHumansPharmacogenomic TestingUnited States
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.